EDAP TMS SA announced the successful treatment of the first patient in its phase I/II PULS Trial, which is investigating the use of High Intensity Focused Ultrasound (HIFU) technology for pancreatic ...

Robotic HIFU therapy continues to maintain an excellent safety profile, confirming positive safety data from prior Phase 1 and 2 studies in patients with deep infiltrating endometriosis At three ...

LYON, France, February 1, 2024 - EDAP TMS SA (EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2) ...

Dublin, March 11, 2020 (GLOBE NEWSWIRE) -- The "Global High Intensity Focused Ultrasound (HIFU) Therapy Market (by Application and Region), Company Profiles, Product Analysis & Recent Development of ...

High-intensity focused ultrasound (HIFU) is a breakthrough therapeutic technique used to treat tumors. The principle of this noninvasive, targeted treatment is much like that of focusing sunlight ...

60 Patients Completed Enrollment in Under 9 Months Study Results Expected in the Second Half of 2024 LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic ...

TOKYO, Feb. 2, 2023 /PRNewswire/ -- SONIRE Therapeutics Inc. (hereinafter referred to as "SONIRE"), based in Tokyo, announces that it has commenced a randomized phase 2 study for the treatment of ...

The 5-year survival rate of pancreatic cancer is very low at 8.5%, and the number of deaths from it in Japan was estimated to be 37,677 patients in 2020, ranking fourth after lung cancer, colorectal ...

According to a new report published by Allied Market Research, titled, "High-intensity Focused Ultrasound (HIFU) Therapy Market by Application: Global Opportunity Analysis and Industry Forecast, ...